+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Sedation R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749245
  • Report
  • February 2019
  • Region: Global
  • 55 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Paion AG
  • Primex Pharmaceuticals Oy
  • Seropeutics LLC
  • Therakind Ltd
  • MORE
The global demand for Sedation treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Sedation pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Sedation pipeline companies from advancing their products into Phase 3 or Phase 4.

Sedation Report Description

The 2019 pipeline study on Sedation pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Sedation pipeline compounds.

The Sedation pipeline guide presents information on all active drugs currently being developed for Sedation. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Sedation pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Sedation drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Sedation product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Sedation pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Sedation pipeline report includes
  • An overview of Sedation disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Sedation pipeline
  • Company wise list of Sedation pipeline
  • Mechanism of Action wise Sedation pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Sedation pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Sedation pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Sedation pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Paion AG
  • Primex Pharmaceuticals Oy
  • Seropeutics LLC
  • Therakind Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Sedation Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Sedation Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Sedation pipeline, H1- 2019
3.5 Mechanism of Action wise Sedation Pipeline Candidates

4 Drawbridge Pharmaceuticals Pty Ltd Sedation Pipeline Details
4.1 Drawbridge Pharmaceuticals Pty Ltd Business Profile
4.2 Drawbridge Pharmaceuticals Pty Ltd Sedation Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Jiangsu Hengrui Medicine Co Ltd Sedation Pipeline Details
5.1 Jiangsu Hengrui Medicine Co Ltd Business Profile
5.2 Jiangsu Hengrui Medicine Co Ltd Sedation Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Jiangsu Nhwa Pharmaceutical Corp Ltd Sedation Pipeline Details
6.1 Jiangsu Nhwa Pharmaceutical Corp Ltd Business Profile
6.2 Jiangsu Nhwa Pharmaceutical Corp Ltd Sedation Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 NanoMedex Pharmaceuticals Inc Sedation Pipeline Details
7.1 NanoMedex Pharmaceuticals Inc Business Profile
7.2 NanoMedex Pharmaceuticals Inc Sedation Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Paion AG Sedation Pipeline Details
8.1 Paion AG Business Profile
8.2 Paion AG Sedation Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Primex Pharmaceuticals Oy Sedation Pipeline Details
9.1 Primex Pharmaceuticals Oy Business Profile
9.2 Primex Pharmaceuticals Oy Sedation Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Seropeutics LLC Sedation Pipeline Details
10.1 Seropeutics LLC Business Profile
10.2 Seropeutics LLC Sedation Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Therakind Ltd Sedation Pipeline Details
11.1 Therakind Ltd Business Profile
11.2 Therakind Ltd Sedation Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. Latest Sedation Drug Pipeline Developments, 2019

13. Appendix
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • NanoMedex Pharmaceuticals Inc
  • Paion AG
  • Primex Pharmaceuticals Oy
  • Seropeutics LLC
  • Therakind Ltd
Note: Product cover images may vary from those shown
Adroll
adroll